OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS

被引:0
|
作者
Spina, Edoardo [1 ,2 ]
Fava, Giuseppina [1 ]
Makos, Xenofon [1 ]
机构
[1] Univ Messina, Dept Clin & Expt Med & Pharmacol, Pharmacol Sect, Policlinico Univ,Via Consolare, I-98125 Messina, Italy
[2] IRCCS, Ctr Neurolesi BoninoPulejo, Messina, Italy
来源
CLINICAL NEUROPSYCHIATRY | 2009年 / 6卷 / 01期
关键词
Antipsychotics; Off label; Bipolar depression; Behavioral and psychological symptoms of dementia; Obsessive-compulsive disorder; Borderline personality disorder; Dopaminergic psychosis; Generalized anxiety disorder;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
All second-generation antipsychotics are licensed for the treatment of schizophrenia. Some of these agents are also approved for the treatment of acute mania and for maintenance therapy of bipolar disorder. In view of a broader spectrum of activity and a more favourable tolerability profile as compared to first-generation compounds, second generation antipsychotics are increasingly used oil-label for the treatment of many psychiatric conditions, either as monotherapy, or as an augmentation strategy. This article reviews the available data concerning the use of second generation antipsychotics in the most common off-label indications in adult and elderly psychiatric patients, such as bipolar depression, behavioural and psychological symptoms of dementia, obsessive-compulsive disorder, borderline personality disorder, dopaminergic psychosis and generalized anxiety disorder.
引用
收藏
页码:11 / 20
页数:10
相关论文
共 50 条
  • [21] Off-label use of second generation antipsychotics in psychiatric inpatients: data from the AMSP study group
    Konstantinidis, A.
    Kutzelnigg, A.
    Moser, U.
    Grohmann, R.
    Sirot, E. Jaquenoud
    Engel, R.
    Kasper, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S455 - S456
  • [22] Off-Label Use of Second Generation Antipsychotics in an Austrian Inpatient Population - Data from the Austrian AMSP
    Konstantinidis, A.
    Moser, U.
    Kutzelnigg, A.
    Grohmann, R.
    Engel, R.
    Kasper, S.
    DRUG SAFETY, 2008, 31 (10) : 952 - 953
  • [23] Off-label use of antipsychotics: are we mad?
    Haw, Camilla
    Stubbs, Jean
    EXPERT OPINION ON DRUG SAFETY, 2007, 6 (05) : 533 - 545
  • [24] Off-label Atypical Antipsychotics
    不详
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 308 (12): : 1198 - 1198
  • [25] Off-Label Use of Atypical Antipsychotics Cause for Concern?
    McKean, Andrew
    Monasterio, Erik
    CNS DRUGS, 2012, 26 (05) : 383 - 390
  • [26] Off-label use of atypical antipsychotics in personality disorders
    Rosenbluth, Michael
    Sinyor, Mark
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (11) : 1575 - 1585
  • [28] Off-label use of second-generation antipsychotics in borderline personality disorder: a comparative real-world study among oral and long-acting injectables in Spain
    Garcia-Carmona, Juan Antonio
    Simal-Aguado, Jorge
    Campos-Navarro, Maria Pilar
    Valdivia-Munoz, Francisco
    Galindo-Tovar, Alejandro
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2021, 36 (04) : 201 - 207
  • [29] Off-label use of antipsychotics in the French psychiatric hospital of Nancy
    Tournebize, J.
    Birkle, C.
    Dobre, D.
    Gibaja, V.
    Kahn, J. P.
    EUROPEAN PSYCHIATRY, 2019, 56 : S143 - S143
  • [30] How to handle off-label prescriptions of rupatadine, a second-generation antihistamine and PAF antagonist: a review
    Izquierdo, Inaki
    Casas, Laia
    Cabrera, Susana
    Fernandez, Alberto
    DRUGS IN CONTEXT, 2024, 13